Abstract:Objective: The prevalence of non-alcoholic fatty liver disease (NAFLD) has markedly increased. Insulin resistance has been implicated in the pathogenesis of NAFLD. This study was aimed at observing the relationship between insulin resistance and NAFLD, and evaluating the role of pioglitazone (PGZ) acting as insulin-sensitizing agents in the prevention and treatment of rat fatty liver induced by high fat feeding. Methods: The rats were separated randomly into 6 groups: model group I were fed high fat diet for 8 weeks, PGZ prevention group were given PGZ 4 mg/(kg·d) simultaneously, while control group I were fed normal food for 8 weeks; model group II were fed high fat diet for 16 weeks, PGZ treatment group were given PGZ 4 mg/(kg·d) orally simultaneous with high fat diet for 8 weeks after high fat feeding for 8 weeks, control group II were fed normal food for 16 weeks. The rats were sacrificed after 8 weeks and 16 weeks respectively. Liver weight, body weight, serum activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), tumor necrosis factor alpha (TNF-α), fasting blood glucose (FBG), fasting plasma insulin (FINS), HOMA (homeostasis model assessment) insulin resistance index (HOMA-IR), and the liver histology of rats of all groups were assayed. Results: After 8 weeks, the liver in model group I showed typical steatosis, accompanied with mild to moderate lobular inflammatory cell infiltration, liver indexes and serum levels of ALT, AST, ALP, TNF-α were significantly increased ( P <0.05) compared with control group I. Whereas, the degree of hepatic injury was attenuated in PGZ prevention group, liver indexes and serum levels of ALT, ALP were significantly decreased ( P <0.05) compared with model group I. After 16 weeks, notable steatosis, and lobular inflammation were observed in model group II rat liver, while the degree of hepatic injury was attenuated in the PGZ treatment group. Liver index, serum levels of ALT, AST, ALP, FINS and HOMA-IR were significantly increased ( P <0.05) in model group II compared with control group II. Whereas, in PGZ treatment group, serum levels of AST and FINS showed decreasing tendency, liver indexes, serum levels of ALT, ALP, TNF-α and HOMA-IR were significantly decreased compared with model group II. Conclusion: Insulin resistance plays a role in the pathogenesis of NAFLD in rats. Pioglitazone can attenuate insulin resistance and biochemical and histological injury in high fat-induced fatty liver in rats.

Association of blood glucose with liver steatosis in non-obese diabetic mice

Association of Nonalcoholic Fatty Liver Disease with Type 2 Diabetes: Clinical Features and Independent Risk Factors in Diabetic Fatty Liver Patients.

Fat-1 Mice Prevent High-Fat Plus High-Sugar Diet-Induced Non-Alcoholic Fatty Liver Disease

Prevention of Strain Fermentation in Hirsutella Sinensis on Type 1 Diabetes of Non-Obese Diabetic Mice

Diabetes Accelerates Steatohepatitis in Mice: Liver Pathology and Single-Cell Gene Expression Signatures

Intrauterine Hyperglycemia Induces Hepatic Steatosis in Mouse Offspring Via Altered Lipid Gene Expressions

Glucose Fluctuation Increased Hepatocyte Apoptosis under Lipotoxicity and the Involvement of Mitochondrial Permeability Transition Opening.

Research on the Protection Effect of Pioglitazone for Non-Alcoholic Fatty Liver Disease (NAFLD) in Rats

The role of mouse hepatic mucosal-associated invariant T cells in the development of type 2 diabetes mellitus

Changes of Gene Expression Profile in Non-Obese Diabetic Mice during the Development of Type 1 Diabetes Mellitus

Comparative study on changes of glycogen metabolism in model mice of diabetes mellitus

Integrated Analysis of Gene Modulation Profile Identifies Pathogenic Factors and Pathways in the Liver of Diabetic Mice.

The impact of different glucose metabolism status on nonalcoholic fatty liver disease in obese patients

Nonalcoholic Fatty Liver Disease and Risk of Diabetes: A Prospective Study in China

Gene Expression Profile Analysis Of Type 2 Diabetic Mouse Liver

Postpartum development of metabolic dysfunction-associated steatotic liver disease in a lean mouse model of gestational diabetes mellitus

The Impact of Obesity on Diabetes Onset and Neovascularization in Mouse Models of Metabolic Stress

Glycemic Measures and Development and Resolution of Nonalcoholic Fatty Liver Disease in Nondiabetic Individuals

Association of iron overload with non-alcoholic fatty liver disease in patients with type 2 diabetes

Oxidative Stress Contributes to Abnormal Glucose Metabolism and Insulin Sensitivity in Two Hyperlipidemia Models

Increased expression of blood serum free fatty acids and cytokeratin 18 in patients with type 2 diabetes with non alcoholic fatty liver disease